GSK licensed EMP‑012, a Phase 1 siRNA candidate from Empirico targeting inflammatory pathways in chronic obstructive pulmonary disease (COPD), paying an $85 million upfront fee and reserving up to $660 million in development, regulatory and commercial milestones plus royalties. GSK positioned the asset as complementary to its respiratory franchise and highlighted potential applicability across non‑type 2 COPD populations. Empirico retains program responsibility while leveraging GSK’s global development and commercialization capabilities. GSK executives noted EMP‑012’s expected long‑acting characteristics and its potential to address patients with limited treatment options, particularly those outside the type‑2 inflammation subgroup.